Compare INTT & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | AVTX |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.3M | 339.9M |
| IPO Year | 1997 | 2015 |
| Metric | INTT | AVTX |
|---|---|---|
| Price | $13.99 | $17.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $13.50 | ★ $36.80 |
| AVG Volume (30 Days) | 139.5K | ★ 805.9K |
| Earning Date | 05-01-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $66,801,000.00 | $27,813,137.00 |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 66.06 | ★ 2312.27 |
| 52 Week Low | $5.24 | $3.39 |
| 52 Week High | $15.66 | $20.72 |
| Indicator | INTT | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 65.28 |
| Support Level | $7.21 | $17.18 |
| Resistance Level | $15.34 | $19.26 |
| Average True Range (ATR) | 0.86 | 1.20 |
| MACD | -0.22 | 0.28 |
| Stochastic Oscillator | 45.17 | 98.63 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).